Tin tức & Cập nhật
Xem bài viết Dược
Xem
Chỉ hiển thị Multimedia
Relacorilant plus nab-paclitaxel prolongs survival in platinum-resistant ovarian cancer
03 Sep 2025
bởiStephen Padilla
The addition of relacorilant to nab-paclitaxel provides survival benefits in patients with platinum-resistant ovarian cancer (PROC) compared with weekly taxane, according to the results of the phase III ROSELLA study, presented at ESMO Gyn 2025.
Relacorilant plus nab-paclitaxel prolongs survival in platinum-resistant ovarian cancer
03 Sep 2025
Atezolizumab plus chemo, bevacizumab improves survival in R/M cervical cancer
02 Sep 2025
bởiStephen Padilla
The addition of atezolizumab to first-line chemotherapy plus bevacizumab delivers significant improvements in survival among patients with PD-L1+ or PD-L1‒ persistent, recurrent, or metastatic (R/M) cervical cancer, results of a post hoc analysis of the BEATcc study have shown.
